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ABSTRACT
Bisphosphonates (BPs) are the most widely used drugs for the treatment of osteoporosis but prolonged use of BPs might increase the
risk of atypical femur fracture (AFF). There are only a few studies that address the bone material quality in patients on long-term BP
treatment with or without AFFs. We analyzed 52 trans-iliac bone biopsies from patients on long-term BP therapy with (n = 26) and
without (n = 26) AFF. At the microscopic level, the degree of mineralization of bone (DMB) was assessed on whole bone by X-ray digitized microradiography while microhardness by Vickers microindentation, and bone matrix characteristics by Fourier transform infrared microspectroscopy (FTIRM) (mineral/organic ratio, mineral maturity and crystallinity, and collagen maturity) were measured at
random focal areas. The AFF patients were treated longer than non-AFF patients (9.7  3.3 years versus 7.9  2.7 years). As expected,
bone remodeling was low in both groups, without difference between them. The AFF group had signiﬁcantly higher DMB in cortical
bone (+2.9%, p = .001), which remained so after adjusting for treatment duration (p = .007), and showed a trend in cancellous bone
(+1.6%, p = .05). Consistent with higher DMB, heterogeneity index (HI) was lower in the AFF than in the non-AFF group, illustrating
lower heterogeneity of mineralization in the AFF group. A signiﬁcant positive correlation between the duration of treatment and
DMB in cortical bone was found in AFF, and not in the non-AFF group. Microhardness and bone matrix characteristics were similar
between groups. We conclude that the AFF group had a duration-dependent increase in DMB leading to a signiﬁcantly higher
DMB than the non-AFF. Because BPs have high afﬁnity to bone mineral and lining the walls of the osteocyte lacunae, the accumulation of matrix-bound BPs in AFF could lead to inhibition of the osteocyte cytoskeleton blunting their response to mechanical strains, a
hypothesis to be further investigated. © 2021 American Society for Bone and Mineral Research (ASBMR).
KEY WORDS: ATYPICAL FEMUR FRACTURE; BISPHOSPHONATES; BONE HISTOMORPHOMETRY; BONE MATRIX MINERALIZATION; MICROINDENTATION

Introduction
typical femur fractures (AFFs) are stress or “insufﬁciency”
fractures, occurring in the subtrochanteric or diaphyseal
region of the femur with minimal or no trauma.(1,2) AFFs are different from classically encountered “typical” proximal femur
fractures, and the American Society for Bone and Mineral
Research (ASBMR) task force has updated in 2014(3) the ﬁrst definition of AFFs.(4) At least four of the ﬁve criteria of AFF are
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required to meet the case deﬁnition. Two of those criteria are
the transverse line through the lateral cortex, and the focal cortical thickness at the fracture line. AFFs arise exclusively on the lateral cortex of the subtrochanteric and diaphyseal regions of the
femur, regions subjected to high mechanical loads,(5) suggesting
that impaired bone matrix quality might predispose to the development of these rare insufﬁciency fractures.
It has been shown that long-term use of bisphosphonates
(BPs), as deﬁned by the ASBMR task force,(6) with reduction in
bone remodeling might increase the risk of AFF.(7,8) However,
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the incidence of AFFs remains low in comparison with the number of avoided osteoporotic fractures,(9) and AFFs may also occur
in patients with no exposure to BPs or with other antiosteoporotic drugs with different mechanism of action such as
denosumab, odanacatib, or romosozumab.(10–12) The risk of
AFF increases with the duration of treatment with BPs,(2,13,14)
and a rapid offset of the risk after discontinuing treatment (risk
is decreased 70% after 1 year discontinuation) has been
reported in one study.(15)
Asians are also at much higher risk for AFF.(9) The exact mechanism for the pathogenesis of AFFs is unknown, but it has been
suggested that the lack of microdamage removal due to prolonged suppression of bone remodeling might lead to
AFF.(16–18) However, why an extremely limited number of
patients treated with BPs develop AFF is still unclear. Few data
on the bone material quality between long-term BP users with
and without AFF are available. We have previously shown that
bone micromechanical properties were compromised in longterm alendronate users without AFF compared to untreated
postmenopausal osteoporotic patients, with a decrease in both
microhardness and crystallinity, while the degree of mineralization of bone (DMB) was increased.(19) Two studies using in vivo
microindentation on mid-tibia failed to show difference in bone
material strength index (BMSi) or in indentation distances
between long-term BP users with or without AFFs.(20,21) A study
using nanoindentation on plastic-embedded proximal femoral
bone showed increased hardness and mineralization in longterm BP users with AFFs compared to long-term BP users with
or without typical fracture.(22) Another study using the same
technique on iliac bone biopsies showed a higher cortical and
cancellous plastic deformation resistance in patients with BPsassociated AFF and a severely suppressed bone remodeling
compared to untreated osteoporotic patients.(23) However, there
is still a lack of knowledge on several other determinants of bone
material quality in long-term BP users with and without AFF, particularly, the DMB, micromechanical properties, and mineral and
organic characteristics.
The purpose of the present study was to examine the bone
material quality in long-term BP users with or without AFF. At
the microscopic level, the DMB was assessed on whole bone by
X-ray digitized microradiography, whereas microhardness by
Vickers microindentation, and bone matrix characteristics were
assessed by Fourier transform infrared microspectroscopy
(FTIRM) (mineral/organic ratio, mineral maturity and crystallinity,
and collagen maturity) were measured at random focal areas. We
hypothesized that long-term BP users with AFF, compared to
long-term BP users without AFF, have a higher DMB, higher
microhardness, and more mature bone matrix characteristics
due to a duration-dependent prolonged secondary mineralization despite similar suppression of bone remodeling.

Materials and Methods
Bone specimens
Twenty-six trans-iliac bone biopsies obtained from outpatient
clinic postmenopausal women with osteoporosis (PMOP) treated
with BPs (9.7  3.5 years) who presented with AFF were compared to 26 biopsies from PMOP patients treated with BPs
(7.9  2.7 years), but without an AFF. Of the 26 non-AFF group,
10 came from our laboratory and were part of a study on the
potential inﬂuence of BPs on the occurrence of microdamage,
that was approved by the Ethics Committee of our Hospital as
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a usual care study (INSERM UMR 1033, Lyon, France), and 16 from
the Bone and Mineral Research Laboratory, Detroit, MI, USA.
Informed consent was obtained from each subject. The study
was approved by the Institutional Review Board of Henry Ford
Hospital. Twenty-ﬁve women were treated with only alendronate (ALN) and one patient was treated with ALN for 7 years
and risedronate for 2 years. Of the 26 AFF group, 10 came from
Quebec City and Montreal, Canada, and 16 were from Detroit,
MI, USA. The biopsies from Canada were done for clinical purpose, and did not require ethical approval. Twenty-four women
were treated with ALN, one with ALN for 3 years followed by
pamidronate for 4.5 years, and another with cyclical etidronate
for 5 years followed by risedronate for 3 years. The majority were
white women with 2 black patients in each group and one Asian
patient in the AFF group.
All bone specimens were embedded in methyl methacrylate
after ﬁxation and dehydration in alcohol. Embedded bone biopsies were cut into 150-μm-thick sections using a precision diamond wire saw (Escil, Chassieu, France), then were ground into
100  1-μm-thick sections and ﬁnally polished with an alumina
suspension (Escil, Chassieu, France) for the measurement of the
degree of mineralization of bone by digitized microradiography.(24) Embedded blocks were polished with an alumina
suspension for the measurement of microhardness by microindentation.(25) Sections 2-μm-thick were cut from embedded
blocks for the analysis of mineral and organic characteristics by
FTIRM analysis.(26–29)

BMD
Bone mineral density (BMD) values by dual-energy X-ray absorptiometry (DXA) at femoral neck, total hip, and lumbar spine were
retrieved at baseline (pretreatment) and at the time of the bone
biopsy in 22 of 26 patients without AFF and 17 of 26 patients
with AFF. Almost all BMD values were measured on Hologic
(Marlborough, MA, USA) with the exception of two patients without AFF and one patient with AFF from Detroit who were measured on GE Lunar (Madison, WI, USA) at baseline with values
converted to Hologic according to Lu and colleagues(30) for femoral neck and total hip BMD, and Hui and colleagues(31) for lumbar spine BMD. DXA measurements were done in each individual
academic institution using established technical standards,
although on different DXA instruments considering the long
delay between baseline and ﬁnal assessments in most patients.

Histomorphometry
The histomorphometric data have been provided on the two
groups, 16 non-AFF and 16 AFF, by the Bone and Mineral
Research Laboratory, Henry Ford Health System Detroit, USA,
and partly published.(32) As the criteria for measurements were
different between the three laboratories (Detroit, Lyon, and Montreal), only the histomorphometric data from the two groups of
16 non-AFF and AFF from Detroit are reported here. All bone histomorphometric variables were designated in accordance with
the nomenclature recommended by the ASBMR.(33) Brieﬂy, the
static histomorphometric indices were measured in sections
stained with the modiﬁed toluidine blue method, and the
dynamic remodeling indices were measured on unstained sections, using a Bioquant image analysis system (Bioquant Image
Analysis Corporation, Nashville, TN, USA) equipped by brightﬁeld and ﬂuorescent microscope. Cortical and cancellous bone
volume/total volume (Ct-BV/TV, Cn-BV/TV; %), cortical and
Journal of Bone and Mineral Research

cancellous wall thickness (Ct-W.th, Cn-W.th; μm), endocortical
and cancellous bone formation rate (Ec-BFR, Cn-BFR; μm3/μm2/
year), endocortical and cancellous activation frequency (Ec-Ac.f,
Cn-Ac.f; #/year), endocortical and cancellous mineralizing surface
(Ec-MS/BS, Cn-MS/BS; %), have been collected from the Henry
Ford Health System laboratory database.

Digitized microradiography
The technique of digitized microradiography was used to measure the DMB and its heterogeneity index (HI).(24) Brieﬂy,
100-μm-thick bone sections were analyzed with a tube Microfocus Hamamatsu X-ray system L9421-02 (Hamamatsu Corporation, Bridgewater, NJ, USA). High voltage of 40 kV, current of
50 μA and power of 2 W were used during X-ray exposure. A
Photonic science CCD camera FDI VHR 11 M (Photonic Science,
Saint Leonards-on-sea, UK) with an active area of 36 × 24 mm
(4008 × 2671 pixels) was used as detector. The image digitization step was done with a 12-bit digital image detector (pixel
size: 9 μm, object pixel size: 0.83 μm).The DMB measurements
by X-ray microradiography are calibrated using hydroxyapatite
calibration phantoms (Skyscan; Bruker, Kontich, Belgium) of
known densities (0.25 and 0.75 g/cm3). Using code from the
MATLAB program (MathWorks, Natick, MA, USA), the gray levels
of images were converted in g/cm3 of bone with the calibration
curve generated from an aluminum-step wedge reference with
eight regular steps (99.5% pure foil; Strem Chemicals Inc., Bischheim, France) that was exposed during the same exposure
conditions. A threshold of 0.6 g/cm3 was applied on the images,
thus only the bone matrix was measured, and the macropores
and micropores were excluded from the measurements of the
DMB. Only the periosteocytic lacunae are included in the DMB
measurement (and thus can slightly decrease the DMB) because
they are thinner than the thickness of the bone sections
(100 μm) used for microradiographs. The mean DMB and mean
HI (HI = full-width at half-maximum of the curve of distribution)
of the DMB were expressed in g mineral/cm3 and measured in
cancellous and cortical bone separately.

FTIRM analysis
FTIRM was used to assess bone material intrinsic properties as
described.(26–29) Brieﬂy, thin bone sections (2-μm thick) were
analyzed in transmission mode with a Perkin-Elmer GXII Autoimage Microscope (Norwalk, CT, USA) equipped with a wide
band detector (mercury-cadmium-telluride) (7800–400 cm−1).
Sixty areas were scanned at 100 μm × 100 μm of spatial resolution (20 areas in each cortex, and 20 areas in cancellous bone)
that were randomly chosen. Each spectrum was collected at
2 cm−1 resolution, 50 scans by spectrum were performed in the
transmission mode, and the contribution from air was subtracted
from original spectrum. The raw spectra were then treated by
automation in the custom Python software (Python Software
Foundation, Fredericksburg, VA, USA) (transformation from
transmittance to absorbance values, removal methyl methacrylate (embedding resin) to extract the components of interest
from a raw spectrum), a baseline correction method, and
curve-ﬁtted with the peak ﬁtting methods.(29) The following variables were determined: the mineral crystallinity (reﬂecting both
crystal size and perfection),(26) and measured as: cryst = 1/fullwidth at half-maximum of the 604 cm−1 peak (apatitic phosphate environment) the mineral to organic ratio (min/org
1184–910 cm−1/1712–1592 cm−1),(34) the mineral maturity (min
Journal of Bone and Mineral Research

mat) which is calculated as the area ratio of the apatitic phosphate over non apatitic phosphate (1030/1110 cm−1 area ratio)
and reﬂects the age of mineral,(26) the carbonation which is the
ratio of the ν2CO3 area (862–894 cm−1) to the ν1ν3PO4 area
(910–1184 cm−1) that reﬂects the incorporation of whole CO3
ions (type B, type A and labile) into the crystal, and the collagen
maturity (coll mat), which is calculated as the ratio of organic
matrix bands (1660/1690 cm−1 area ratio).(27,28) Results are
expressed as mean  standard deviation (SD) for each bone
envelope (cortical or cancellous).

Microhardness testing
A Vickers indenter was used to measure microhardness on
polished blocks (Micromet 5104; Buehler, Lake Bluff, IL, USA).(25)
Brieﬂy, a test load of 25 g applied for 10 s was used for each
indentation. For each sample, 60 indents (20 in each cortical
and 20 in cancellous bone) were performed at the tissue level,
and randomly chosen. Microindentations were performed in randomly selected areas of the bone surface, separated by at least
500 μm over the whole bone tissue area.
The sizes of the impressions were measured from the direct
measurement of diagonal dimensions using manufacturer software (Omnimet HMS v.2.31; Buehler), and the microhardness
(Hv) was derived using the following formulae Hv = 1854.4 P/
d2 (where Hv is Vickers microhardness expressed in kg/mm2, P
is test load in kg, and d is the mean length of the two diagonals
expressed in mm). Results are expressed as mean  SD for each
bone envelope (cortical or cancellous).

Statistical analyses
Analyses were performed using SPSS® 16.0 (SPSS Inc., Chicago,
IL). A t test was carried out using SigmaStat (Systat Software
Inc., San Jose, CA, USA) for the histomorphometric analysis. Differences between non-AFF and AFF were assessed using nonparametric Mann-Whitney tests and differences in BMD before
and after treatment using nonparametric Wilcoxon tests. The
associations between DMB, mineral and collagen characteristics,
local mechanical properties, and remodeling variables were
tested using Spearman’s correlations (rho). Adjustments of
DMB, mineral characteristics, and collagen characteristics for
the duration of treatment were performed using an ordinal
regression. A p value <.05 was used to deﬁne statistical
signiﬁcance.

Results
Age, BMI, and duration of treatment by BPs
Age and BMI at the time of bone biopsy were not signiﬁcantly
different between non-AFF and AFF. However, the mean duration of treatment was signiﬁcantly longer in the AFF group than
in the non-AFF group (9.7  3.3 years versus 7.9  2.7 years;
p = .03; Table 1). The range of the duration of treatment was
2 to 17 years in the AFF group and 3 to 15 years in the nonAFF, respectively.

BMD before and after treatment
Before treatment femoral neck and lumbar spine BMDs were
similar in non-AFF and AFF groups, but total hip BMD was higher
in the AFF group (p = .03; Fig. 1). After long-term BP treatment,
total hip and lumbar spine BMDs (mean %  SD) signiﬁcantly
ATYPICAL FEMUR FRACTURE: SECONDARY MINERALIZATION
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Table 1. Age, BMI, Duration of Treatment, and Histomorphometric Data in Non-AFF and AFF Groups
Parameter
Age, BMI, and duration of treatment, mean  SD
Age
BMIa
Duration of treatment by BPs (years)
Histomorphometry
Cortical
Ct BV/TV (%)
Ct-W.th (μm)
Ct-BFR (μm3/μm2/year)
Ct-Ac.f (/year)
Ct-MS/BS (%)
Cancellous
Cn BV/TV (%)
Cn-W.Th (μm)
Cn-BFR (μm3/μm2/year)
Cn-Ac.f (/year)
Cn-MS/BS (%)

Non-AFF

AFF

p

(n = 26)
68.2  5.9
24.7  5.1
7.9  2.7
(n = 16)

(n = 26)
66.4  5.4
26.8  5.0
9.7  3.3
(n = 16)

NS
NS
p = .03

95.36  1.64
41.34  5.35
5.23  6.25
0.13  0.15
3.34  2.95

95.50  2.47
37.45  5.07
4.69  6.21
0.14  0.19
3.71  4.09

NS
p = .04
NS
NS
NS

16.32  8.47
32.70  5.21
1.63  2.64
0.05  0.08
1.13  1.46

13.16  4.13
29.00  3.58
1.00  1.86
0.03  0.06
0.91  1.26

NS
p = .03
NS
NS
NS

NS = not statistically signiﬁcant.
a
BMI: n = 22 in non-AFF; n = 21 in AFF.

Fig 1. BMD measured by DXA before and after treatment in non-AFF and AFF groups, at femoral neck, total hip, and lumbar spine. BMD = bone mineral
density.

increased from baseline in AFF (total hip: 3.95  5.6%; p = .01;
lumbar spine 9.41  5.98%; p = .0003) but remained unchanged
in the non-AFF group (Fig. 1). The BMD increase at total hip in
AFF remained signiﬁcant after adjustment for the duration of
treatment (p = .03).

Bone histology and histomorphometry
All biopsies were evaluated for histology and showed a normal
lamellar bone texture, with no evidence of pathological ﬁndings
such as osteomalacia, woven bone, or marrow ﬁbrosis. No significant differences were found in static variables (Ct-BV/TV and CnBV/TV) except in Ct-W.Th and Cn-W.Th, which were lower in the
AFF compared to the non-AFF group (p ≤ .04). Dynamic variables
of bone remodeling as reﬂected by BFR, Ac.f and MS/BS were not

n4

FARLAY ET AL.

signiﬁcantly different between the groups in either cortical or
cancellous bone (Table 1).

DMB
The distribution of the mineralization is illustrated on microradiographs of iliac bone samples from patients with or without
AFF (Fig. 2C-D). In the AFF group, we found signiﬁcantly higher
DMB in cortical bone (+2.9%, p = .001) than in non-AFF and a
trend toward a similar change in cancellous bone (+1.6%,
p = .05, Fig. 2A) After adjusting for the duration of BP treatment,
the DMB was still signiﬁcantly higher in cortical bone (p = .007)
but not in cancellous bone. Although we found a decrease in
HI in cortical (trend, p = .05) and cancellous (p < .007, Fig. 2B)
bone in the AFF group when compared to non-AFF, the
Journal of Bone and Mineral Research

Fig 2. (A) DMB (g/cm3) and (B) HI (g/cm3) in non-AFF and AFF groups. DMB values were signiﬁcantly higher and HI lower in AFF group compared to nonAFF in cortical and cancellous bone. (C,D) X-ray digitized microradiographs of 100-μm-thick section of iliac bone from (C) non-AFF (woman treated 8 years
with alendronate) and (D) AFF (woman treated 9 years with alendronate). DMB = degree of mineralization of bone; HI = heterogeneity index.

difference between the groups disappeared after adjusting for
the duration of BP treatment in cortical bone but persisted in
cancellous bone (p = .09 and p = .02, respectively). No adjustments for age were needed because mean age and distribution
were similar.

groups, were tested. A signiﬁcant positive correlation
(rho = 0.468; p < .02) between the duration of treatment and
DMB was only shown in cortical bone from the AFF group
(Fig. 3A, right). No other correlation was found between the
duration of treatment and the other variables, microhardness,
and mineral/organic characteristics (Fig. 3B-D).

Mineral and organic characteristics
FTIRM analysis of iliac bone samples showed no signiﬁcant differences in mineral/matrix ratio, crystallinity, mineral maturity, carbonation, or collagen maturity between non-AFF and AFF
groups when assessed in both cortical and cancellous bone tissues (Table 2).

Microhardness
No signiﬁcant difference was found in microhardness between
non-AFF and AFF groups, neither in cortical nor in cancellous
bone tissues (Table 2).

Correlations between the duration of treatment and DMB,
microhardness, and mineral/organic characteristics
Correlations between the duration of BPs treatment and DMB,
crystallinity and microhardness, separately in non-AFF and AFF
Journal of Bone and Mineral Research

Discussion
The purpose of the present study was to compare bone material
quality in trans-iliac bone biopsies from patients with and without AFF after long-term BP therapy. Both groups had histomorphometrically conﬁrmed low remodeling. As we hypothesized,
DMB was higher in cortical (borderline in cancellous bone) and
HI lower in cancellous (borderline in cortical bone), in the AFF
compared to the non-AFF group. However, the higher DMB in
AFF was not associated with a signiﬁcantly lower bone remodeling. Because patients with AFF were treated for signiﬁcantly longer duration than non-AFF patients (2 additional years on
average), this higher DMB could potentially be explained by a
longer duration of treatment. However, after adjustment for
the duration of treatment, the DMB remained signiﬁcantly
higher in the AFF group than in the non-AFF group. When
ATYPICAL FEMUR FRACTURE: SECONDARY MINERALIZATION
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Table 2. Bone Material Properties in Non-AFF and AFF Groups
Property
Microindentation
Cortical microhardness (Ct-Hv)
Cancellous microhardness (Cn-Hv)
FTIRM analysis
Cortical
Ct-Min/org ratio
Ct-Crystallinity
Ct-Mineral maturity
Ct-Carbonation
Ct- Collagen maturity
Cancellous
Cn-Min/org ratio
Cn-Crystallinity
Cn-Mineral maturity
Cn-Carbonation
Cn- Collagen maturity

Non-AFF (n = 26)

AFF (n = 26)

p

51.2  3.6
53.5  3.0

52.8  3.0
54.9  2.8

NS
NS

4.8  0.3
0.038  0.001
1.9  0.6
0.0070  0.0005
4.4  0.6

4.9  0.3
0.038  0.001
2.0  0.5
0.0071  0.0006
4.5  0.6

NS
NS
NS
NS
NS

4.8  0.4
0.038  0.001
1.7  0.4
0.0072  0.0006
4.0  0.6

4.9  0.4
0.038  0.002
1.7  0.4
0.0073  0.0009
4.2  0.7

NS
NS
NS
NS
NS

NS = not statistically signiﬁcant.

correlated and analyzed separately, the AFF group had a
duration-dependent increase in DMB, not found in the non-AFF
group. As expected, we also found a lower HI in the AFF group
compared to the non-AFF, indicating a lower heterogeneity of
bone mineralization in AFF. The BMD measurements are consistent with our material property results, conﬁrming a signiﬁcant
gain of bone mineral density in the AFF group after treatment,
at both lumbar spine and total hip, that was not observed in
non-AFF patients. Also, this higher BMD in AFF-group persisted
at the total hip after adjustment for the duration of treatment,
as observed for DMB. Microhardness and others mineral and
organic characteristics were not signiﬁcantly different between
the groups. As AFFs, by deﬁnition, occur in femur that is composed mainly of compact bone, the discussion will now focus
mostly on cortical bone.
Atypical femur fracture is a rare complication of long-term BP
treatment and the pathogenesis is not yet fully elucidated. Concern has arisen that long-term BP use may increase the risk of
AFF through several putative mechanisms including a prolonged
reduction in bone remodeling and consequently a delayed
microcracks repair. Incidence rates of AFF range from 1.8 per
100,000 cases per year with a 2-year BP exposure to 113.1 per
100,000 cases per year with BP exposure from 8 to 9.9 years.(3,35)
AFFs also occur in treatment-naïve patients, or in patients treated
with osteoporosis medications other than BPs.(1) Thus, a low bone
remodeling, universally found with antiresorptive drugs, does not
seem to be sufﬁcient, but perhaps necessary, to cause AFFs, as
illustrated by the low incidence rate (8 per 100,000 person-years)
reported with the prolonged use of denosumab (up to 7 or
10 years), whereas it is a more potent antiresorptive,(36) and in
treatment-naive postmenopausal women with osteoporosis. Furthermore, several cases of AFFs were associated with odanacatib,
a cathepsin K inhibitor with antiresorptive effect but attenuated
reduction of bone formation.(37)
The percentage difference in DMB of cortical bone between
non-AFF and AFF (+2.9%), accounts for approximately one-third
of the difference of DMB after 2 years of ALN compared with a
placebo group as previously shown by our group (+9.3%,
p = .004).(38) The increase in DMB after 2 years of ALN was close
to the increase in BMD assessed by DXA at the lumbar spine
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(+8.7% at 2 years), suggesting that the improved bone strength
after ALN was mainly explained by the increase in DMB. It results
from the completion of mineralization of bone structural units
(BSUs) by extension of the secondary mineralization subsequent
to the reduction in activation frequency. BMD measured by DXA
depends on both bone mass and bone tissue degree of mineralization. Consistent with the higher DMB in AFF group after treatment, we also found higher BMD in AFF at total hip and lumbar
spine, despite no difference in baseline BMD between non AFF
and AFF groups, except at the total hip. After treatment, total
hip and lumbar spine BMDs were signiﬁcantly increased from
baseline in AFF but remained unchanged in non-AFF. This might
be explained in part by BMD measurement inaccuracies due to
the long period between the 2 measurements (up to 17 years)
and changes in DXA instruments. It is likely that BMDs increased
in both groups but due to these measurement inaccuracies, only
the higher increases in BMDs in AFF group were signiﬁcant. This
increase in BMD in the AFF group could favor a continuous
adsorption of bisphosphonates on bone mineral matrix and
potential interaction with osteocytes entrapped in the bone
matrix.
The most notable ﬁnding was an unexpected durationdependent increase in DMB found only in the AFF group,
because DMB should not increase further once the plateau of
mineralization is reached, which usually occurs after about
3 years of treatment.(38,39) Indeed, in non-AFF, DMB no longer
increases once a new equilibrium of bone turnover is reached
after 2 to 3 years of BPs (ﬁrst increases and then stabilizes)
whereas in AFF it continues to increase. Present values of bone
mineralization were compared to historical values obtained in
patients treated with denosumab (DMAb; FREEDOM study [Fracture Reduction Evaluation of Denosumab in Osteoporosis Every
6 Months])(40) known to have a greater antiresorptive effect than
BPs. Values obtained with DMAb at 2 to 3 years of treatment
were higher than those obtained in AFF group treated 10 years
on average (Supplementary Fig. S1). The DMB under DMAb continued to increase until 5 years in FREEDOM Extension and
reached a plateau from 5 to 10 years.(40) This is consistent with
the lower values of HI with DMAb than BPs. Thus, the plateau
of mineralization was reached later with DMAb than with BPs
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Fig 3. Spearman’s correlations between duration of treatment with bisphosphonates and (A) Ct DMB, (B) Ct-HI, (C) Ct-crystallinity, and (D) Ct-microhardness, separately in non-AFF group (left panels) and in AFF group (right panels). A statistically signiﬁcant positive correlation was only found in AFF group
between Ct-DMB and duration of treatment. Ct = cortical.
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(5 versus 3 years of treatment; Supplementary Fig. S1). Despite a
higher DMB with DMAb, and a much smaller and shorter clinical
use, the incidence rate of AFFs with DMAb is lower than with oral
bisphosphonate (8 vs 113.1/100,000 cases per year) and is not
duration-dependent. Thus, it appears that the impact of BPs is
more dependent on duration of adsorption to bone matrix than
the duration or potency of their antiresorptive effect (and thus of
the magnitude of bone remodeling suppression). Several studies
showed that long-term users of BPs (≥5 years) have increased
AFF risk than short-term users of BPs, supporting this
reasoning.(41)
Microhardness was not different between non-AFF and AFF
groups, whereas higher values were expected in the AFF group
as DMB was increased. Indeed, DMB and microhardness often
evolve in the same way, as previously shown in control or
untreated osteoporotic bone,(25) but not always, especially in
BPs-treated osteoporotic bone.(19) By histomorphometry,
although there was no difference in dynamic bone turnover
variables between AFF and non-AFF, both cortical and cancellous W.Th were signiﬁcantly lower (p = .04, p = .03, respectively)
in AFF than in non-AFF, meaning that the interstitial bone volume was higher in AFF. This could explain why a higher DMB
was found in AFF than non-AFF by X-ray microradiography
(measured on the entire whole-bone section), whereas no differences were detected by microhardness focal measurements. However, the values of microhardness in non-AFF and
AFF groups were within physiological range and similar to
values found in healthy women after menopause.(42) Vickers
microindentation performed in the present study was not able
to differentiate the respective contributions related to elastic
and plastic parts, as with nanoindentation or instrumented
indentation. Thus, the percentage of increase in the DMB in
AFF group compared to non-AFF (+2.9%) might be too low to
produce a signiﬁcant increase in microhardness values that
could be measured by Vickers microindentation. A study performed by nanoindentation on a subset of the bone biopsies used
in the present study (14 biopsies in each group from Detroit)
showed that elastic modulus was higher in cortical bone with
AFF than without AFF (EAFF = 16.18  0.12 GPa versus ENonAFF
= 15.83  0.11 GPa, p = .0448), and that plastic energy (damage) was greater in AFF than in non-AFF.(43) Thus, impact of the
small increase in DMB on elastic modulus was highlighted with
nanoindentation.
No differences were reported between both groups in variables measured by FTIRM, indicating that there were no differences in crystal size, mineral maturity, mineral/organic ratio,
carbonation, or collagen maturity between AFF and non-AFF
groups. A higher mineral/organic ratio in AFF group was
expected as a higher DMB (absolute value of mineralization)
was observed in this group. As for microhardness, FTIRM measurements were assessed as focal measurements whereas
DMB consider the entire bone section. Furthermore, mineral/
organic ratio is a relative value of mineralization (organic content may simultaneously increase). Because no difference in
bone remodeling activity was found between both groups,
the absence of difference in the FTIRM variables is not surprising, because the variables measured have likely reached their
“plateau”. Crystallinity was decreased in long-term alendronate
users (6.4  2.0 years), compared with untreated PMOP
women, and this was associated with a decrease of the microhardness.(39) These two variables were not modiﬁed in nonAFF and AFF groups, likely because patients in both groups
were treated with BPs. However, as for microhardness data,
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the values of bone intrinsic variables measured by FTIRM in
non-AFF and AFF groups were within physiological range and
similar to values found in healthy women after menopause.(42)
Other mechanisms involved in bone fragility and not assessed
in this study might also have a role in the genesis of AFF. First,
the accumulation of microcracks has been suggested to
increase with the duration of BPs therapy.(44) Nonetheless, we
have shown that the microcrack frequency in the iliac bone of
long-term BPs users was low, despite the marked reduction in
bone remodeling, compared to controls (iliac bone from
cadavers).(45) It should be noted that femoral stress fractures initiate in the lateral cortex (area with high tensile stresses), and
are affected by the femoral geometry (greater lateral curvature
and varus alignment in AFF).(46) Thus, as the mechanical strain is
high is this area, the microcrack frequency is perhaps much
higher than in iliac bone where the mechanical load is low. Second, another signiﬁcant factor in bone fragility is the presence
of advanced glycation end products (AGEs), known to reduce
the capacity of bone matrix to dissipate energy.(47) AGEs exponentially increases with age and with senescence of tissues.(48)
Because the AFF group was treated longer on average than
non-AFF, and bone remodeling being consequently decreased
longer, bone matrix from AFF likely contains more AGEs than
non-AFF. However, this needs to be conﬁrmed by additional
studies.
The main result of this study is that the duration-dependent
increase in DMB after long-term BP therapy leads to a signiﬁcantly higher DMB in AFF than in non-AFF patients. However,
all the values were within the physiological range, for microhardness and others variables assessed by FTIRM, indicating an
absence of deleterious effect of BPs on bone characteristics
assessed in this study. Numerous recent studies highlighted
the role of osteocytes in the local regulation of mineral homeostasis by sensing the mineralization levels in the surrounding
matrix, while the mechanisms are still unknown.(49,50) Recently,
in a mouse model, it has been shown that a deletion of receptor
tyrosine kinase ligand Ephrin-B2 in osteocytes led to osteocyte
autophagy and to a higher and more rapid secondary mineralization and matrix maturation than wild-type mice. While the primary mineralization was normally initiated, a brittle bone
phenotype was observed, making the Ephrin-B2 as a potential
candidate for the regulation of secondary mineralization and
limitation of mineral accumulation.(51,52) Both elevated exocytic
matrix vesicles production and autophagy were observed in
those osteocytes deﬁcient in Ephrin B2. Thus, EphrinB2 suppresses autophagic processes and limits matrix vesicle release
via RhoA-ROCK signaling.
Furthermore, alendronate inhibits farnesyl pyrophosphate
synthase, an enzyme in the mevalonate pathway needed to produce geranylgeranyl groups, and affects the osteoblast actin
cytoskeleton (and also osteoclasts) through impairing the activation of RhoA.(53)
In osteoblasts, autophagy is involved in mineralization and
bone homeostasis through the autophagic vacuoles used as
vehicles in osteoblasts to secrete apatite crystals, and an autophagy deﬁciency reduces the mineralization capacity.(54) Zoledronic acid has been shown to induce autophagy in breast cancer
cells.(55) Considering the strong binding afﬁnity of BPs for
hydroxyapatite,(56) their presence around the osteocyte lacunae
and around the lacuna-canalicular osteocyte network,(57) their
long-term accumulation in AFF might disrupt the ability of osteocytes to regulate the mineral homeostasis during the secondary
mineralization and sense the mechanical strains.
Journal of Bone and Mineral Research

Our study has several limitations. First, the sample size is small
although noticeable for this rare condition, and duration of therapy was longer in the AFF group. Second, bone biopsies were not
obtained at the site of AFF with potential differences in bone
material quality between non-weight-bearing and weightbearing bones. Third, others intrinsic bone properties of women
with AFF might differ even before therapy from those without
AFF, which might not be captured by our retrospective design.
In conclusion, the AFF group had a BP therapy durationdependent increase in DMB leading to a signiﬁcantly higher
DMB than the non-AFF mainly in cortical bone, which persisted
even after adjustment for the duration of treatment. Considering
the high afﬁnity of BPs to bone mineral, and their lining along the
walls of the osteocyte lacunae, the accumulation of matrix
bound BPs in AFF could lead to inhibition of the osteocyte cytoskeleton, blunting their response to mechanical strains. This
hypothesis remains to be further investigated.
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